E. MOTEVALIZADEH, A. DÍAZ-LÓPEZ, F. MARTÍN, J. BASORA and V. ARIJA
2023 Oct 7; . doi:10.1210/clinem/dgad594; PMID:37804535
Context Little is known about whether parity is associated with elevated early-pregnancy insulin resistance (IR), or whether overweight/obesity contributes to increasing the possible effect.Objective We determined the associations between parity and glucose metabolism parameters in the first trimester of pregnancy in a Mediterranean pregnant population, and whether these associations are affected by overweight/obesity.Methods A cross-sectional study was conducted of 264 healthy pregnant women from the ECLIPSES study who were recruited at 12 weeks of gestation. At baseline, details on socioeconomic status, obstetric history (including parity, ie, number of births), lifestyle factors, anthropometry, and blood samples were collected. Fasting serum glucose, insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) index were assessed in the first trimester. Elevated IR was defined as the upper HOMA-IR tertile (>= 1.58). Multivariable linear regression and Cox regression model with constant time were performed.Results Parity ranged from 0 to 4. After multivariable adjustment, the insulin levels (beta [% change]: 20.92; 95% CI, 4.08-37.71) and HOMA-IR index (beta [% change]: 19.72; 95% CI, 2.43-40.49) were positively associated with parity. Additionally, multiparous women, as compared to nulliparous, were more likely to have higher HOMA-IR levels (primiparous [1 birth], beta [% change[: 16.88; 95% CI, -1.00 to 37.99; multiparous [>= 2 births), beta [% change]: 32.18; 95% CI, 3.56-68.71), and an increased relative risk (RR) of an elevated IR (primiparous [1 birth], RR: 1.55; 95% CI, 1.03-2.36; multiparous (>= 2 births), RR: 1.72; 95% CI, 1.05-2.83). The combination of multiparity and overweight/obesity conferred a 3.04-fold increase in the RR of elevated IR, which increased proportionally to the number of parities.Conclusion This study demonstrates that parity may have a negative effect on early-pregnancy IR and that maternal overweight/obesity appears to further aggravate this relationship.
M. RAETHKE, N. LUXI, G. TRIFIRÒ, N. THURIN, D. MENTZER, E. DE CLERCQ, B. KOVACIC, K. MORTON, F. MARQUES, S. SONDERLICHOVÁ, F. VILLALOBOS, F. RIEFOLO, F. VAN HUNSEL and M. STURKENBOOM
2023 Oct 1;
C. DURÁN, S. BELITSER, S. BOTS, F. RIEFOLO, D. MESSINA, R. GINI, P. GARCÍA-POZA, M. PÉREZ, J. CARRERAS, E. CORRECHER-MARTÍNEZ, A. URCHUEGUÍA, P. SOUVEREIN, F. VILLALOBOS, J. RIERA-ARNAU, A. SCHULTZE, I. DOUGLAS, O. KLUNGEL and M. STURKENBOOM
2023 Oct 1;
P. ROMERO-AROCA, R. VERGES, J. PASCUAL-FONTANILLES, A. VALLS, J. FRANCH, J. BARROT, X. MUNDET, A. LA TORRE, A. MORENO, R. SAGARRA, J. BASORA, E. GARCIA-CURTO and M. BAGET-BERNALDIZ
2023 Oct 1; . doi:10.3390/jcm12206674; PMID:37892811
(1) Background: Diabetic retinopathy (DR) remains the leading cause of low vision and blindness in young adults of working age. Although the most important risk factors-such as the duration of diabetes mellitus (DM) and glycemic control measured by HbA1c-are known, the effects of lipids are not as clear. The aim of the present study is to analyze the effects of lipids on the development of DR. (2) Methods: This is a retrospective study of a population of 175,645 DM2 patients, during the period 2010 to 2020, in which the effects of different lipid factors are studied. (3) Results: The variables that most influenced the development of DR in our study, based on significance and cumulative hazard (CH), were arterial hypertension (CH 1.217, p < 0.001), HbA1c levels (CH 1.162, p = 0.001), microalbuminuria (CH 1.012, p < 0.001), LDL-C cholesterol (CH 1.007, p = 0.012), TC/HDL-C index (CH 1.092, p < 0.001), No-HDL-C/HDL-C index (CH 1.065, p = 0.002), the use of statins (CH 1.001, p = 0.005), and body mass index (CH 1.007, p < 0.001). (4) Conclusions: LDL-cholesterol, TC/HDL-C, and No-HDL-C/HDL-C indices are related to the development of DR, and there is a protective effect of HDL-cholesterol and the use of fibrates.
W. AARTS, J. CHOI, D. ROY, C. FRY, S. LANE, R. GINI, A. GIRARDI, O. PAOLETTI, F. VILLALOBOS, C. BISSACCO, E. SEGUNDO, A. LUPATTELLI, J. ZHAO, D. WEIBEL, D. ESPOSITO, D. MARTIN, S. ST LAURENT, M. EMILEBACKER, V. EHRENSTEIN, S. SORUP and B. GOODALE
2023 Oct 1;